Asset Details
Do you wish to reserve the book?
ESRA19-0271 Intrathecal administration of hyperbaric prilocaine is a source of systemic O-toluidine
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
ESRA19-0271 Intrathecal administration of hyperbaric prilocaine is a source of systemic O-toluidine
Do you wish to request the book?
ESRA19-0271 Intrathecal administration of hyperbaric prilocaine is a source of systemic O-toluidine
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
ESRA19-0271 Intrathecal administration of hyperbaric prilocaine is a source of systemic O-toluidine
2019
Overview
Background and aimsHyperbaric 2% prilocaine (HP) is increasingly used for spinal anesthesia. It is the only local anesthetic metabolized to o-toluidine, a human bladder carcinogen. Massive increase of o-toluidine hemoglobin adducts (HAoT), a marker of o-toluidine carcinogenic pathway, was described following subcutaneous injection. In the present study we aimed to assess a single intrathecal dose of HP as a source of HAoT and urinary o-toluidine (UoT).MethodsAfter ethical committee approval and informed written consent, 10 patients undergoing surgery received 50 mg of HP intrathecally. Blood and urine samples were collected before injection and up to 24 hours later.UoT and HAoT were measured by tandem mass-spectrometry after gas-chromatographic separation. Values are expressed as mean ± standard deviation. Pair Students t-test was used for the significance tests.ResultsIntrathecal administration of 50 mg of HP leads to a massive increase of HAoT (0.11±0.02 to 11.59±1.89 ng/g Hb after 24h, p<0.0001, figure 1). Peak of UoT was observed after 8h (0.1±0.1 to 351.6±352.7 µg/L, p<0.001) and declined to 80.0±66.8 µg/L after 24h (figure 2).Abstract ESRA19-0271 Figure 1Abstract ESRA19-0271 Figure 2ConclusionsIntrathecal administration of HP leads to a relevant systemic burden of carcinogenic o-toluidine. Therefore, the carcinogenic risk of HP administration should be the object of ethical considerations and further clinical investigations.
Publisher
BMJ Publishing Group LTD
Subject
